Abstract

Carbon monoxide (CO) poisoning is a potentially life-threatening condition that typically requires prompt administration of high-concentration oxygen, most commonly delivered via a non-rebreather mask (NRB). While this method remains the standard of care, high-flow nasal cannula (HFNC) therapy has gained popularity as an effective alternative for oxygen delivery in various respiratory disorders. HFNC provides heated and humidified oxygen at high flow rates, which may offer physiological benefits such as improved oxygenation, reduced work of breathing, and enhanced patient comfort. This case report describes an innovative application of HFNC in the acute management of CO poisoning. The patient presented with elevated carboxy-haemoglobin levels and was successfully treated using HFNC rather than conventional NRB therapy. This case highlights the potential role of HFNC as a feasible and effective option in the treatment of CO poisoning and encourages further investigation into its utility in similar toxicological emergencies.

• 1.   Hampson N.B. U.S. Mortality due to carbon monoxide poisoning, 1999–2014. accidental and intentional deaths. Ann Am Thorac Soc. 2016; 13(10): 1768-74.
• 2.   Carbon monoxide exposures–United States, 2000–2009. MMWR. 2011; 60(30): 1014-7.
• 3.   Department of Health and Social Care. 2023. https://www.gov.uk/government/news/ nhs-to-expand-services-to-keep-vulnerableout-of-hospital
• 4.   Tomruk O., Karaman K., Erdur B., et al. A New promising treatment strategy for carbon monoxide poisoning: high flow nasal cannula oxygen therapy. Med Sci Monit. 2019;25:605-9.
• 5.   Ozturan I.U., Yaka E., Suner S., et al. Determination of carboxyhemoglobin halflife in patients with carbon monoxide toxicity treated with high flow nasal cannula oxygen therapy. Clin Tox (Phila). 2019; 57(7): 617-23.
• 6.   Hardy KR, Thom SR. Pathophysiology and treatment of carbon monoxide poisoning. J Toxicol Clin Toxicol. 1994; 32(6): 613-29.
• 7.   Rose J.J., Wang L., Xu Q., et al. Carbon monoxide poisoning: pathogenesis, management, and future directions of therapy. Am J Respir Crit Care Med. 2017; 195(5): 596-606.
• 8.   Peterson J.E., Stewart R.D. Absorption and elimination of carbon monoxide by inactive young men. Arch Environ Health. 1970; 21(2): 165-71.
• 9.   Lenglet H., Sztrymf B., Leroy C.,et al.Humidified high flow nasal oxygen during respiratory failure in the emergency department: feasibility and efficacy. Respir Care. 2012; 57(11): 1873-8.
• 10.   Parke R.L., Eccleston M.L., McGuinness S.P. The effects of flow on airway pressure during nasal high-flow oxygen therapy. Respir Care. 2011; 56(8): 1151-5.
• 11.   Parke R.L., McGuinness S.P.. Pressures delivered by nasal high flow oxygen during all phases of the respiratory cycle. Respir Care. 2013; 58(10): 1621-4.
• 12.   Sztrymf B., Messika J., Bertrand F., et al. Beneficial effects of humidified high flow nasal oxygen in critical care patients: a prospective pilot study. Intensive Care Med. 2011; 37(11): 1780-6.
• 13.   Franklin D., Babl F.E., Schlapbach L.J., et al. A randomized trial of high-flow oxygen therapy in infants with bronchiolitis. N Engl J Med. 2018; 378(12): 1121-31.

Data Sharing Statement

Funding